Evidence for neuroprotection by the fenamate NSAID, mefenamic acid
Neurochemistry International, ISSN: 0197-0186, Vol: 55, Issue: 7, Page: 683-688
2009
- 39Citations
- 8Usage
- 41Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations39
- Citation Indexes39
- 39
- CrossRef37
- Usage8
- Abstract Views8
- Captures41
- Readers41
- 41
Article Description
Fenamate NSAIDs are inhibitors of cyclooxygenases, antagonists of non-selective cation channels, subtype-selective modulators of GABA A receptors, weak inhibitors of glutamate receptors and activators of some potassium channels. These pharmacological actions are all implicated in the pathogenesis of ischemic stroke. The aim of this study was to investigate the hypothesis that the fenamate, mefenamic acid, is neuroprotective in an in vitro and in vivo model of stroke.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0197018609002009; http://dx.doi.org/10.1016/j.neuint.2009.06.014; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=69349094657&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/19563851; https://linkinghub.elsevier.com/retrieve/pii/S0197018609002009; https://scholarlycommons.pacific.edu/phs-facarticles/412; https://scholarlycommons.pacific.edu/cgi/viewcontent.cgi?article=1411&context=phs-facarticles; https://dx.doi.org/10.1016/j.neuint.2009.06.014
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know